摘要
2014年西非埃博拉疫情暴发后,多个埃博拉疫苗临床试验陆续开展。开展临床试验的埃博拉疫苗主要是病毒载体类疫苗,例如人腺病毒载体(Ad5和Ad26)、3型黑猩猩腺病毒载体(Ch Ad3)、水泡性口炎病毒载体(VSV)、痘病毒载体(MVA)。从免疫策略上来说,包括单次免疫与初免-加强两种免疫策略。基于Ad5、Ad26、Ch Ad3和MVA载体的埃博拉疫苗在Ⅰ、Ⅱ期临床试验中显示了良好的免疫原性,基于VSV载体的疫苗更是在Ⅲ期临床试验中显示了很好的保护性。
Several clinical trials for Ebola vaccines started after Ebola epidemic outbreak in 2014. Ebola vac-cines in the clinical trials mainly focused on viral vectors, such as human adenovirus vector（Ad5 and Ad26）,Chimpanzee adenovirus vector（chAd3）, vesicular stomatitis virus vector（VSV）, vaccinia vector（MVA）. Different vac-cination strategies were used in the clinical trials, including one immunization and prime- boost immunization.Those Ebola vaccines based on Ad5, Ad26, ChAd3 and MVA vectors showed good immunogenicity in phase Ⅰand phase Ⅱ clinical trials, and Ebola vaccine based on VSV vector showed protection efficacy in phase Ⅲ clini-cal trial.
作者
侯利华
HOU Li-Hua(Beijing Institute of Biotechnology, Beijing 100071, China)
出处
《生物技术通讯》
CAS
2017年第1期35-43,共9页
Letters in Biotechnology
